Aktienanalyse zu AngioDynamics, Inc. (ANGO)ANGOAngioDynamics, Inc.

AngioDynamics, Inc. is a transformative medical technology company. The Company is focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving quality of life for patients. It designs, manufactures, and sells a range of medical, surgical and diagnostic devices used by professional healthcare providers for vascular access, for the treatment of peripheral vascular disease and for use in oncology and surgical settings. Its devices are generally used in minimally invasive, image-guided procedures. Its segments include Med Tech and Med Device. The Med Tech segment is comprised of its technology portfolio including Auryon, the thrombus management platform and NanoKnife. The Med Device segment includes its Core, Venous, Ports and other Oncology products. Its product types are Ablation, Catheters, Medical Balloons, and Ports. The Catheter products include Angiographic Catheters, Uni-Fuse Infusion Catheter and Drainage Catheters. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

AngioDynamics Inc is a good buy right now due to its recent strong performance and positive catalysts. The current price is $15.85, and the company reported a 25% year-to-date change, alongside a significant 8% revenue growth in Q4 2026. The RSI is at 57.545, indicating a healthy momentum. However, the main risk is the forward P/E ratio of 96.15, suggesting that the stock may be overvalued based on future earnings expectations.

5 analysts cover ANGO: 1 rate it Buy, 4 Hold and 0 Sell. The average price target is 19.33.